JAL39 Antibody
Description
Research Context
AtJAL39 is studied in the context of monocot-dicot chimeric protein interactions. Arabidopsis JRL proteins (e.g., AtJAX1) and DIR proteins (e.g., AtDIR19) have been tested for their ability to confer resistance to powdery mildew in barley. While AtJAL39 was paired with AtDIR11 in functional assays, no physical interaction was observed .
| Protein Pair | Interaction Status | Functional Implication |
|---|---|---|
| AtDIR11 + AtJAL39 | No physical interaction | Limited co-operation in pathogen resistance |
| AtDIR19 + AtJAX1 | Functional interaction | Enhanced resistance to Bgh penetration |
Lack of Interaction with AtDIR11
In domain-swapping experiments:
-
AtJAL39 did not physically interact with AtDIR11, contrasting with other JRL-DIR pairs (e.g., AtDIR19 + AtJAX1) .
-
This suggests functional redundancy or specificity in JRL-DIR partnerships.
Role in Powdery Mildew Resistance
-
AtJAX1/AtDIR19 significantly reduced Bgh penetration in barley epidermal cells.
-
AtJAX1 was essential for resistance, while AtJAL39 showed no measurable contribution in transient overexpression assays .
Mechanistic Insights
The absence of interaction between AtJAL39 and AtDIR11 implies that:
-
JRL-DIR partnerships are context-dependent.
-
AtJAL39 may require specific co-factors or post-translational modifications to function.
Potential Applications
-
Crop Engineering: Understanding non-interacting JRL-DIR pairs could refine strategies for transferring pathogen resistance across species.
-
Protein Engineering: Structural studies of AtJAL39 may reveal conserved motifs for targeted modification.
Q&A
Based on the provided search results and established antibody research methodologies, here is a structured FAQ addressing key scientific considerations for antibody research. While "JAL39 Antibody" isn't specifically mentioned in the sources, this framework adapts validated approaches from comparable studies:
Advanced Research Questions
How to address antigenic drift in therapeutic antibody development?
Case study framework from CV38-142:
Methodological recommendation:
-
Implement deep mutational scanning every 6 months for emerging variants
-
Use RosettaAntibodyDesign for affinity maturation (10^6 sequence library capacity )
How to resolve conflicting serological data from immunization studies?
Analytical framework from JE-CV antibody persistence modeling :
| Model Type | Application | Advantage |
|---|---|---|
| Piecewise linear mixed | Long-term antibody decay | Captures biphasic decline (R²=0.94) |
| Bayesian hierarchical | Small cohort extrapolation | Reduces CI width by 40% vs frequentist |
Contradiction resolution protocol:
-
Re-test >3 independent antigen batches
-
Validate epitope integrity via HDX-MS
-
Compare animal vs human PBMC responses
Structural Validation Standards
What orthogonal techniques confirm antibody-epitope engagement?
| Technique | Resolution | Throughput |
|---|---|---|
| Cryo-EM single particle | 3.2-4.1 Å | Medium (2-4 weeks) |
| Hydrogen-deuterium exchange MS | 1-5 residue | High (96 samples/day) |
| Negative stain EM | 10-20 Å | High (100+ samples/week) |
Case example: mAb 72.1 LPS binding required immuno-FESEM to confirm surface accessibility
